Clinical Trial: Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic

U.S., Sept. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07807345) titled 'Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic' on Aug. 31.

Brief Summary: This study is a first-in-human (FIH) Phase 1 open-label, multicenter study including three parts:

* Part 1A is a dose escalation of STRO-006 monotherapy in selected tumor types reported to commonly express ITGB6. Part 1A will determine the safety, tolerability, pharmacokinetics (PK), and preliminary anti-tumor activity of STRO-006.

* Part 1B is a dose expansion in one or more indications, as determined by the Sponsor, to further evaluate a STRO-006 monotherapy dose, examine anti-tumor activity, and determin...